- Private coverage of the payer’s health plan in Canada for Enerzair Breezhaler and Atectura Breezhaler reached 80%
- Reimbursement procedures with publicly funded health plans ready to start
MONTREAL, June 1, 2021 / CNW Telbec / – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo“or the”Society“), a Canadian pharmaceutical company, today announced that private health insurance plans currently cover 80% of those privately insured in Canada agreed to reimburse Enerzair Breezhaler and Atectura Breezhaler.
Enerzair Breezhaler and Atectura Breezhaler are two innovative new therapies for asthma approved for use in Canada.
“Asthma therapies are largely covered by private payers representing 50% of the total market. Reimbursement of Enerzair and Atectura is now available for the majority of covered persons Canada and reimbursement procedures from public health plans are ready to begin, ”said Frédéric Fasano, Chairman and CEO of Valeo. “Both drugs have shown, in direct comparison to standard of care, clinically significant improvement in asthma-related symptoms, lung function and the rate of exacerbations. These strong clinical value propositions have been essential to achieve the current level of private coverage ”.
About Enerzair Breezhaler
Enerzair Breezhaler is indicated for maintenance treatment of asthma in adult patients insufficiently controlled by a maintenance combination of a long-acting beta.2-agonist and a medium or high dose of an inhaled corticosteroid. This formulation combines the bronchodilation of indacaterol acetate (a LABA) and glycopyrronium bromide (an AMLA) with mometasone furoate (an ICS) in a precise once-daily formulation, delivered via the Breezhaler device upon confirmation dose.
About Atectura Breezhaler
Atectura Breezhaler is indicated as a once-daily maintenance treatment for asthma in adults and adolescents 12 years of age and older with reversible obstructive airway disease. Atectura Breezhaler should be prescribed to patients whose long-term asthma control is insufficient, such as ICS, or whose severity of disease clearly warrants treatment with both LABA and ICS. Atectura Breezhaler combines the bronchodilation of indacaterol acetate (an LAMA) with the anti-inflammatory mometasone furoate (an ICS) in a precise once-daily formulation, delivered via the Breezhaler dose-confirmation device.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on pulmonology, neurodegenerative diseases, oncology and other specialty products. Based at Kirkland, Quebec, Valeo Pharma has all the capabilities and a complete infrastructure to register and properly manage its growing portfolio of products at all stages of marketing. For more information, visit www.valeopharma.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements about Valeo’s objectives, strategies and activities which involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.
SOURCE Valeo Pharma inc.
For further information: Valeo Pharma, Steve Saviuk, CEO, 514 693-8830, [email protected], Or, Frédéric Dumais, Director of Communications and Investor Relations, 514-782-8803, [email protected]